{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:40:52Z","timestamp":1789555252634,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82373440"],"award-info":[{"award-number":["No. 82373440"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"DelMar Pharmaceuticals Inc"},{"name":"Cancer Innovative Research Program of Sun Yat-sen University Cancer Center","award":["CIRP-SYSUCC-PT13120101"],"award-info":[{"award-number":["CIRP-SYSUCC-PT13120101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04235-y","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T09:16:07Z","timestamp":1765530967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study"],"prefix":"10.1007","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct03050736","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chengcheng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuhua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Langlands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarath","family":"Kanekal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"10","key":"4235_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"15","key":"4235_CR2","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1158\/1078-0432.CCR-06-0596","volume":"12","author":"A Chakravarti","year":"2006","unstructured":"Chakravarti A, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006;12(15):4738\u201346.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4235_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/14737140.1.1.13","volume":"1","author":"SJ Danson","year":"2001","unstructured":"Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001;1(1):13\u20139.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"4235_CR4","first-page":"2585","volume":"6","author":"HS Friedman","year":"2000","unstructured":"Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585\u201397.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4235_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","volume":"23","author":"ES Newlands","year":"1997","unstructured":"Newlands ES, et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23(1):35\u201361.","journal-title":"Cancer Treat Rev"},{"issue":"32","key":"4235_CR6","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4235_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"issue":"6","key":"4235_CR8","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","volume":"10","author":"ME Hegi","year":"2004","unstructured":"Hegi ME, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10(6):1871\u20134.","journal-title":"Clin Cancer Res"},{"key":"4235_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1075559","author":"T Johanssen","year":"2023","unstructured":"Johanssen T, et al. Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2022.1075559.","journal-title":"Front Oncol"},{"key":"4235_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/OTT.S366371","volume":"16","author":"E Pineda","year":"2023","unstructured":"Pineda E, et al. Recurrent glioblastoma: ongoing clinical challenges and future prospects. Oncotargets Ther. 2023;16:71\u201386.","journal-title":"Oncotargets Ther"},{"issue":"11","key":"4235_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1586\/era.10.161","volume":"10","author":"R Stupp","year":"2010","unstructured":"Stupp R, Hegi M, Weller M. Neuro-oncology, a decade of temozolomide and beyond. Expert Rev Anticancer Ther. 2010;10(11):1675\u20137.","journal-title":"Expert Rev Anticancer Ther"},{"key":"4235_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1158\/1538-7445.AM2016-2985","volume":"76","author":"B Zhai","year":"2016","unstructured":"Zhai B, et al. Molecular mechanisms of dianhydrogalactitol (VAL-083) in cancer treatment. Cancer Res. 2016;76:615.","journal-title":"Cancer Res"},{"key":"4235_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1069-9","author":"B Zhai","year":"2018","unstructured":"Zhai B, et al. Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination. Cell Death Dis. 2018. https:\/\/doi.org\/10.1038\/s41419-018-1069-9.","journal-title":"Cell Death Dis"},{"issue":"2","key":"4235_CR14","first-page":"283","volume":"66","author":"RT Eagan","year":"1982","unstructured":"Eagan RT, et al. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol. Cancer Treat Rep. 1982;66(2):283\u20137.","journal-title":"Cancer Treat Rep"},{"issue":"8","key":"4235_CR15","first-page":"1647","volume":"66","author":"RT Eagan","year":"1982","unstructured":"Eagan RT, et al. Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. Cancer Treat Rep. 1982;66(8):1647\u20139.","journal-title":"Cancer Treat Rep"},{"issue":"5","key":"4235_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/BF00304764","volume":"24","author":"E Institoris","year":"1989","unstructured":"Institoris E, et al. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol. Cancer Chemother Pharmacol. 1989;24(5):311\u20133.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4235_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000401484","volume":"23","author":"FM Schabel Jr","year":"1978","unstructured":"Schabel FM Jr, et al. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother. 1978;23:200\u201315.","journal-title":"Antibiot Chemother"},{"key":"4235_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/neuonc\/nou255.18","volume":"16","author":"S Fouse","year":"2014","unstructured":"Fouse S, et al. VAL-083 is a novel N7 alkylating agent that inhibits the growth of glioma stem and non-stem cultures, including temozolomide-resistant lines. Neuro Oncol. 2014;16:200.","journal-title":"Neuro Oncol"},{"key":"4235_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1158\/1538-7445.AM2012-811","volume":"72","author":"K Hui","year":"2012","unstructured":"Hui K, et al. VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme. Cancer Res. 2012;72:811.","journal-title":"Cancer Res"},{"key":"4235_CR20","first-page":"3","volume":"12","author":"M van den Bent","year":"2010","unstructured":"van den Bent M, et al. Updated response assessment criteria for high-grade gliomas (HGG): report from the response assessment in neuro-oncology (RANO) working group. Neuro Oncol. 2010;12:3\u20133.","journal-title":"Neuro Oncol"},{"key":"4235_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/neuonc\/nou226","volume":"16","author":"PY Wen","year":"2014","unstructured":"Wen PY, et al. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014;16:36\u201347.","journal-title":"Neuro Oncol"},{"key":"4235_CR22","unstructured":"Common terminology criteria for adverse events (CTCAE) Version 4.0. 2009."},{"issue":"2","key":"4235_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2307\/2530454","volume":"38","author":"JR Anderson","year":"1982","unstructured":"Anderson JR, Bernstein L, Pike MC. Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics. 1982;38(2):407\u201316.","journal-title":"Biometrics"},{"issue":"8","key":"4235_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709\u201322.","journal-title":"N Engl J Med"},{"issue":"8","key":"4235_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"5","key":"4235_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/neuonc\/nou356","volume":"17","author":"LB Nabors","year":"2015","unstructured":"Nabors LB, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17(5):708\u201317.","journal-title":"Neuro Oncol"},{"issue":"7","key":"4235_CR27","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1093\/neuonc\/nox204","volume":"20","author":"N Schaefer","year":"2018","unstructured":"Schaefer N, et al. Quality of life in the GLARIUS trial randomizing bevacizumab\/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol. 2018;20(7):975\u201385.","journal-title":"Neuro Oncol"},{"issue":"23","key":"4235_CR28","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1001\/jama.2015.16669","volume":"314","author":"R Stupp","year":"2015","unstructured":"Stupp R, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma a randomized clinical trial. JAMA. 2015;314(23):2535\u201343.","journal-title":"JAMA"},{"issue":"4","key":"4235_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/glioma.glioma_25_19","volume":"2","author":"Department of Neurosurgery\/Neuro-Oncology, S.Y.-s.U.C.C., Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province","year":"2019","unstructured":"Department of Neurosurgery\/Neuro-Oncology, S.Y.-s.U.C.C., Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangzhou, Guangdong Province, et al. Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): halfway report. Glioma. 2019;2(4):167\u201373.","journal-title":"Glioma"},{"issue":"1","key":"4235_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/nop\/npac069","volume":"10","author":"PYM Woo","year":"2023","unstructured":"Woo PYM, et al. Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period. Neuro Oncol Pract. 2023;10(1):50\u201361.","journal-title":"Neuro Oncol Pract"},{"key":"4235_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa082","author":"I Alnahhas","year":"2020","unstructured":"Alnahhas I, et al. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neuro Oncol Adv. 2020. https:\/\/doi.org\/10.1093\/noajnl\/vdaa082.","journal-title":"Neuro Oncol Adv"},{"issue":"1","key":"4235_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/noac099","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023;25(1):123\u201334.","journal-title":"Neuro Oncol"},{"issue":"7","key":"4235_CR33","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/neuonc\/now312","volume":"19","author":"SK Tanguturi","year":"2017","unstructured":"Tanguturi SK, et al. Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017;19(7):908\u201317.","journal-title":"Neuro Oncol"},{"issue":"2","key":"4235_CR34","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4143\/crt.2020.847","volume":"53","author":"H Kang","year":"2021","unstructured":"Kang H, et al. A nationwide, population-based epidemiology study of primary central nervous system tumors in Korea, 2007\u20132016: a comparison with United States data. Cancer Res Treat. 2021;53(2):355\u201366.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"4235_CR35","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noae047","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, et al. CBTRUS statistical report: American Brain Tumor Association & NCI Neuro-Oncology Branch Adolescent and Young Adult Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020. Neuro Oncol. 2024;26(3):iii1\u201353.","journal-title":"Neuro Oncol"},{"key":"4235_CR36","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.2147\/CMAR.S291681","volume":"13","author":"C Zeng","year":"2021","unstructured":"Zeng C, et al. Comprehensive molecular characterization of Chinese patients with glioma by extensive next-generation sequencing panel analysis. Cancer Manag Res. 2021;13:3573\u201388.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"4235_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/neuonc\/noac217","volume":"25","author":"F Girardi","year":"2023","unstructured":"Girardi F, et al. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000\u20132014 (CONCORD-3). Neuro Oncol. 2023;25(3):580\u201392.","journal-title":"Neuro Oncol"},{"issue":"1_Supplement","key":"4235_CR38","doi-asserted-by":"publisher","first-page":"A109","DOI":"10.1158\/1535-7163.TARG-17-A109","volume":"17","author":"B Zhai","year":"2018","unstructured":"Zhai B, et al. Abstract A109: DNA-damaging agent dianhydrogalactitol (VAL-083) targets HR repair pathway and suggests combination therapy with topoisomerase and PARP inhibitors. Mol Cancer Ther. 2018;17(1_Supplement):A109\u2013A109.","journal-title":"Mol Cancer Ther"},{"key":"4235_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01006-4","author":"B Subramaniam","year":"2025","unstructured":"Subramaniam B, et al. Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models. NPJ Precis Oncol. 2025. https:\/\/doi.org\/10.1038\/s41698-025-01006-4.","journal-title":"NPJ Precis Oncol"},{"issue":"13_Supplement","key":"4235_CR40","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1158\/1538-7445.AM2019-1051","volume":"79","author":"A Golebiewska","year":"2019","unstructured":"Golebiewska A, et al. Abstract 1051: Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo. Cancer Res. 2019;79(13_Supplement):1051\u20131051.","journal-title":"Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04235-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T17:36:05Z","timestamp":1768844165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04235-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04235-y","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Sun Yat\u2011sen University Cancer Center (B2016\u2011058\u201101) on January 13, 2017, China, and registered with the ClinicalTrials.gov (NCT03050736) on February 13, 2017. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors certify that they have obtained the appropriate participant consent form. In the forms, the participants have given their consent for the participants\u2019 images and other clinical information to be reported in the journal. The participants understood that their names and initials would not be published and due efforts would be made to conceal their identity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standards of reporting"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}